ADAP

Adaptimmune Therapeutics

0.2779 USD
+0.0132
4.99%
At close May 16, 4:00 PM EDT
After hours
0.2700
-0.0079
2.84%
1 day
4.99%
5 days
-7.37%
1 month
15.79%
3 months
-52.28%
6 months
-53.29%
Year to date
-55.43%
1 year
-76.84%
5 years
-94.70%
10 years
-98.33%
 

About: Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

Employees: 506

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

167% more call options, than puts

Call options by funds: $24K | Put options by funds: $9K

7% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 14

1.78% less ownership

Funds ownership: 9.89% [Q3] → 8.1% (-1.78%) [Q4]

3% less funds holding

Funds holding: 80 [Q3] → 78 (-2) [Q4]

14% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 21

50% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]

54% less capital invested

Capital invested by funds: $144M [Q3] → $67M (-$77.1M) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$0.46
66%
upside
Avg. target
$1.52
448%
upside
High target
$3
980%
upside

5 analyst ratings

positive
60%
neutral
20%
negative
20%
Barclays
Peter Lawson
15% 1-year accuracy
4 / 27 met price target
66%upside
$0.46
Underweight
Maintained
14 May 2025
Wells Fargo
Yanan Zhu
11% 1-year accuracy
1 / 9 met price target
260%upside
$1
Equal-Weight
Maintained
14 May 2025
HC Wainwright & Co.
Arthur He
9% 1-year accuracy
3 / 32 met price target
980%upside
$3
Buy
Maintained
1 Apr 2025
Guggenheim
Michael Schmidt
38% 1-year accuracy
17 / 45 met price target
530%upside
$1.75
Buy
Maintained
26 Mar 2025
Scotiabank
George Farmer
9% 1-year accuracy
2 / 22 met price target
404%upside
$1.40
Sector Outperform
Maintained
21 Mar 2025

Financial journalist opinion

Based on 3 articles about ADAP published over the past 30 days

Neutral
Seeking Alpha
3 days ago
Adaptimmune Therapeutics plc (ADAP) Q1 2025 Earnings Call Transcript
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Cintia Piccina - Chief Commercial Officer Dennis Williams - SVP, Late Stage Development Gavin Wood - CFO John Lunger - VP, Manufacturing Conference Call Participants Marc Frahm - TD Cowen Jonathan Chang - SVB Leerink Arthur He - H.C. Wainwright Graig Suvannavejh - Mizuho Yanan Zhu - Wells Fargo Securities Operator Hello and welcome to Adaptimmune's First Quarter 2025 Business Update Conference Call.
Adaptimmune Therapeutics plc (ADAP) Q1 2025 Earnings Call Transcript
Neutral
Newsfile Corp
3 days ago
Adaptimmune Reports Q1 Financial Results and Provides Business Update
TECELRA ® launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced $4.0 million Tecelra net sales in Q1 2025 Instituting 2025 Tecelra full year sales guidance of $35-$45 million Lete-cel on track to initiate rolling BLA submission late 2025; approval anticipated in 2026 Adaptimmune had Total Liquidity 1 of $60 million as of March 31, 2025; call at 8 a.m. EDT today Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 13, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reported financial results and provided a business update for the first quarter ended March 31, 2025.
Adaptimmune Reports Q1 Financial Results and Provides Business Update
Neutral
Newsfile Corp
1 week ago
Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter of 2025, before the US markets open on Tuesday, May 13, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m.
Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025
Neutral
Seeking Alpha
1 month ago
Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q4 2024 Earnings Conference Call March 20, 2025 8:00 AM ET Company Participants Juli Miller - IR Adrian Rawcliffe - CEO Cintia Piccina - Chief Commercial Officer Gavin Wood - CFO Dennis Williams - SVP, Late Stage Development John Lunger - VP, Manufacturing and Supply Chain Conference Call Participants Jonathan Chang - Leerink Partners Tony Butler - Rodman & Renshaw Graig Suvannavejh - Mizuho George Farmer - Scotiabank Arthur He - H.C. Wainwright Michael Kim - Zacks Small Cap Research Peter Lawson - Barclays Operator Hello, and welcome to the Adaptimmune's Q4 and Full Year 2024 Business Update Conference Call.
Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript
Neutral
Newsfile Corp
1 month ago
Adaptimmune Provides Q4 and Full Year 2024 Business Update
TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achieved Lete-cel on track to initiate rolling BLA submission late 2025; approval anticipated 2026 Corporate restructure completed in February 2025 and implementing additional cost reduction for PRAME and CD70 programs At the end of 2024, Adaptimmune had Total Liquidity 1 of $152 million Evaluating all strategic options to maximize shareholder value Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today provided a Q4 and Full Year 2024 business update. Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: "2025 is the year of commercial execution for Tecelra, as we begin to generate value from our promising sarcoma franchise.
Adaptimmune Provides Q4 and Full Year 2024 Business Update
Neutral
Newsfile Corp
2 months ago
Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2024, before the US markets open on Thursday, March 20, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m.
Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025
Neutral
Newsfile Corp
3 months ago
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will participate in the Guggenheim Securities SMID Cap Biotech Conference this February. Guggenheim Securities SMID Cap Biotech Conference, New York, NY Fireside chat with Adrian Rawcliffe, CEO: February 6 at 3:00 p.m.
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025
Neutral
Newsfile Corp
4 months ago
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
The Company will present at the Annual J.P. Morgan Healthcare Conference, providing business updates on its sarcoma franchise and other cell therapy pipeline assets Adaptimmune Allo-T program to be featured at the Biotech ShowCase (TM) and the Wuxi Global Forum 2025 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 13, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that letetresgene autoleucel (lete-cel), has been granted breakthrough therapy designation by the U.S. FDA for the treatment of patients with unresectable or metastatic myxoid/round cell liposarcoma (MRCLS) who have received prior anthracycline-based chemotherapy, are positive for HLA-A*02:01, HLA-A*02:05, or HLA-A*02:06, and whose tumor expresses the NY-ESO-1 antigen.
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
Neutral
Newsfile Corp
4 months ago
Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK
Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31, 2025 Gavin Wood, Chief Financial Officer, will step down from the Company May 31, 2025 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 19, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that two of its executive leadership team members based in the UK will leave the Company next year.
Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK
Neutral
Newsfile Corp
5 months ago
First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)
Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 2, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that the first patient has been treated with TECELRA® (afamitresgene autoleucel). TECELRA is the first engineered cell therapy for a solid tumor cancer approved in the U.S., and the first new therapy option in more than a decade for synovial sarcoma, a rare, soft tissue cancer that most commonly impacts young adults.
First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)
Charts implemented using Lightweight Charts™